MERIDIANGSK plc
Live view: Yahoo
Identity (GLEIF Global LEI Index)
| Field | Value | Class |
|---|---|---|
| Legal name | GSK plc | SF |
| LEI | Unavailable | SF |
| Swiss UID | Not in GLEIF record | SF |
| Jurisdiction | gb | SF |
| Legal address | 79 New Oxford Street, London, WC1A 1DG | SF |
| Headquarters | SF | |
| Entity status | Active | SF |
| Geneva connection | unresolved | CM |
Listed securities (SIX Swiss Exchange issuer directory)
| ISIN | Ticker | MIC | Share class | Segment | Accounting standard | Next GM | Auditor | Prov. |
|---|---|---|---|---|---|---|---|---|
| GSK | — | not announced | — | ⓘ |
Market snapshot
1916.50 GBp
Stale — 11 days old · delayed per exchange agreement · yahoo
| Metric | Value | Class |
|---|---|---|
| SMA 20 | 1962.88 | CM |
| SMA 50 | 1927.92 | CM |
| 52-week range position | 62% of range 1344.00–2268.00 | CM |
| Trend (SMA20 vs SMA50) | up | CM |
| History depth | 254 daily bars | SF |
Analyst price targets
| Low | Mean | Median | High | Analysts | Provider | As of |
|---|---|---|---|---|---|---|
| 1455.0 | 2139.0498 | 2010.0 | 2825.0 | 20 | yahoo_analyst | 2026-07-18T22:50:42Z |
Consensus recommendation (provider-published): hold
Financials (latest reported period)
Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.
Period ending 2025-12-31 (annual) · reported in GBP
| Metric | Value | Class |
|---|---|---|
| Revenue | 32.7B GBP | CD |
| Gross profit | 23.6B GBP | CD |
| Operating income | 7.9B GBP | CD |
| EBITDA | not disclosed | CD |
| Net income | 6.3B GBP | CD |
| EPS | 1.39 | CD |
2 further data fields this platform tracks — no connected source covers this issuer yet. Shown to demonstrate capacity; each populates automatically when a source does, and nothing is estimated in the meantime. Show what is tracked ›
Recent company events
News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.
No company events ingested yet — the FMP rotation families (news, insider transactions, congressional disclosures, analyst estimates) populate this once a key is configured. Nothing is invented in the meantime.
Segment & geographic revenue (company disclosures)
Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.
No disclosed segment or geographic revenue ingested for this company yet. The Business Quant pipeline (SEC-parsed company disclosures) reaches US-listed issuers progressively within its daily budget; issuers that do not disclose segment detail keep this honest state.
How the company makes money
Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. SF
source: wikipedia · retrieved 2026-07-19
Sector: biotechnology, pharmaceutical industry peers
Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.
Corporate registry (OpenCorporates)
Official company-registry data aggregated by OpenCorporates; each value carries the registry's own snapshot date. Officers appear only where the registry publishes them (Swiss registries do not). The presence sweep lists same-name registrations across jurisdictions as labelled inference — never asserted subsidiaries.
Status: Active · Legal form: Public Limited Company · Incorporated: 1999-12-06 · Registered address: 79 New Oxford Street, London, WC1A 1DG · OC jurisdiction: gb · registry record ↗ · registry snapshot as of 2026-07-18
Officers (69 on register):
- LUKE VICTOR MIELS — director (since 2026-01-01)
- GAVIN ROBERT SCREATON — director (since 2025-05-01)
- JEANNIE TSUN-HUEI LEE — director (since 2024-03-04)
- WENDY MIRA BECKER — director (since 2023-10-01)
- JULIE BELITA BROWN — director (since 2023-05-01)
- ELIZABETH MCKEE ANDERSON — director (since 2022-09-01)
Regulators of highest concern
Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.
| Authority | Jur. | Matches | Max applicability | Max confidence |
|---|---|---|---|---|
| EU Publications Office (EU law) | EU | 15 | 0.65 | 0.78 |
| us_congress | US | 11 | 0.65 | 0.78 |
| Health and Human Services Department | US | 7 | 0.65 | 0.78 |
| SECO / WBF (Swiss sanctions & trade) | CH | 2 | 0.65 | 0.78 |
| General Services Administration | US | 1 | 0.65 | 0.78 |
Regulatory exposure — matches with evidence
The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.
| Rule | Instrument | Relationship | Applicability | Confidence | Exposure | Potential price impact (inference) | Review |
|---|---|---|---|---|---|---|---|
| R-SECTOR-DATA_PRIVACY_TECH | FINMA Risk Monitor 2025: accentuated geopolitical risks – cyber and real estate risks cont | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a Swiss data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Abs | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant S | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerv | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regardin | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | General Services Acquisition Regulation; Acquisition of Information and Communication Tech | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1022R(01): Corrigendum to Commission Delegated Regulation (EU) 2026/1022 of 30 | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | CELEX:32026D1416: Commission Implementing Decision (EU) 2026/1416 of 30 June 2026 setting | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1022: Commission Delegated Regulation (EU) 2026/1022 of 30 April 2026 amending | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1457: Commission Implementing Regulation (EU) 2026/1457 of 29 June 2026 on the | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1461: Regulation (EU) 2026/1461 of the European Parliament and of the Council | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1455: Regulation (EU) 2026/1455 of the European Parliament and of the Council | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1463: Council Regulation (EU) 2026/1463 of 25 June 2026 amending Regulation (E | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1465: Council Regulation (EU) 2026/1465 of 25 June 2026 amending Regulation (E | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1422: Commission Implementing Regulation (EU) 2026/1422 of 25 June 2026 amendi | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | CELEX:32026R1451: Commission Delegated Regulation (EU) 2026/1451 of 20 March 2026 amending | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1540: Commission Implementing Regulation (EU) 2026/1540 of 6 July 2026 imposin | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-PHARMA_HEALTH | Recission of the National Cancer Institute Clinical Cancer Education Program Regulation | sector_topic_candidate_pharma_health | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 9601 (119th Congress): To direct the United States Trade Representative to initiate inv | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | HR 9183 (119th Congress): Artificial Intelligence Environmental Impacts Act of 2026 | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | HR 9492 (119th Congress): Cybersecurity Logging Enforcement and Accountability Reporting A | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | S 4883 (119th Congress): A bill to amend the Export Control Reform Act of 2018 to increase | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | S 4840 (119th Congress): Export Control Enforcement and Enhancement Act | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 8169 (119th Congress): Export Control Enforcement and Enhancement Act | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | S 4214 (119th Congress): Artificial Intelligence Data Center Moratorium Act | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | HR 9442 (119th Congress): Artificial Intelligence Data Center Moratorium Act | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 4326 (119th Congress): To require the Congressional Budget Office to conduct an economi | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | HRES 1340 (119th Congress): Expressing strong opposition to the imposition of digital serv | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 8770 (119th Congress): SAFEGUARDS Act of 2026 | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | FINMA guidance on quantum computing | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a Swiss data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026D1760: Political and Security Committee Decision (CFSP) 2026/1760 of 14 July 20 | sector_topic_candidate_tariffs_trade_remedies | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | CELEX:32026R1714: Council Implementing Regulation (EU) 2026/1714 of 13 July 2026 implement | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | CELEX:32026D1713: Council Decision (CFSP) 2026/1713 of 13 July 2026 amending Decision (CFS | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-DATA_PRIVACY_TECH | CELEX:32026D1725: Council Implementing Decision (EU) 2026/1725 of 10 July 2026 authorising | sector_topic_candidate_data_privacy_tech | 0.65 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU data-privacy / technology measure: if it applied it could raise compliance costs or constrain data-driven revenue lines, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
Recent filings — potential impact inputs
A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.
| Filed | Form | Title | Document |
|---|---|---|---|
| 2026-07-01 | 6-K | 6-K — GSK plc | document |
| 2026-06-29 | 6-K | 6-K — GSK plc | document |
| 2026-06-29 | 6-K | 6-K — GSK plc | document |
| 2026-06-26 | 6-K | 6-K — GSK plc | document |
| 2026-06-24 | 6-K | 6-K — GSK plc | document |
| 2026-06-24 | 6-K | 6-K — GSK plc | document |
| 2026-06-23 | 6-K | 6-K — GSK plc | document |
| 2026-06-22 | 6-K | 6-K — GSK plc | document |
| 2026-06-17 | 6-K | 6-K — GSK plc | document |
| 2026-06-15 | 6-K | 6-K — GSK plc | document |